Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8807161 | Annals of Diagnostic Pathology | 2018 | 6 Pages |
Abstract
Clones evaluated in this study had a high level of concordance with IHC despite PR (1E2) demonstrating higher analytical binding properties than other clones. In a minority of cases (1.3% for 1E2 and 2.5% for 636) IHC results could convert estrogen receptor (ER)â/PRâ to ERâ/PR+ tumors, making these patients potentially eligible for endocrine therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
Benjamin C. Calhoun, Brian Mosteller, Daniel Warren, Margie Smith, J. Jordi Rowe, Christopher P. Lanigan, Karen C. Mrazeck, Espen Walker, Amy Hanlon Newell, Raymond Jones,